uniQure (QURE) Q1 2026 earnings review
Regulatory Realities Collide with Premature Commercial Spend
uniQure's Q1 2026 results highlight a jarring divergence between operational realities and financial positioning. The FDA formally dashed hopes for an accelerated US approval of the lead Huntington's candidate, AMT-130, requiring a new clinical trial. Consequently, the US regulatory pathway is reversing. However, the company is pivoting rapidly, accelerating an ex-US strategy with a UK regulatory submission planned for Q3 2026. A glaring red flag emerged on the income statement: SG&A expenses nearly doubled YoY to $20.1 million, driven by 2025 commercial hires for a US launch that is now years away. With $586.6 million in cash, the runway stretches into H2 2029, buying time to absorb pipeline attrition (the ALS program was formally scrapped), but management must address the misaligned operating expense structure.
🐂 Bull Case
With $586.6M in cash and current investments, uniQure has a runway into the second half of 2029, removing near-term financing overhangs despite heavy clinical setbacks.
Following a successful pre-submission meeting, the UK MHRA appears willing to review AMT-130 based on existing data, setting up an MAA submission in Q3 2026 that could yield revenue far earlier than the US.
🐻 Bear Case
The FDA definitively rejected the use of Phase I/II data compared to an external control for a BLA. A new clinical trial design is required, adding massive delays and costs to the lead asset.
The AMT-162 ALS program was officially discontinued due to safety/efficacy reviews, and the mid/high doses of the AMT-191 Fabry program remain paused due to liver toxicities.
⚖️ Verdict: 🔴
Bearish. The US market is the ultimate prize for AMT-130, and the FDA's demand for a new trial destroys the near-term investment thesis. The massive spike in SG&A for a delayed commercial launch highlights capital allocation inefficiencies.
Key Themes
US Regulatory Pathway Reversing for AMT-130
The FDA Type A meeting confirmed the worst-case scenario: the agency will not accept Phase I/II data with an external control for a BLA. Management is now forced to schedule a Type B meeting in Q2 2026 to discuss a new clinical trial design. This completely unwinds the accelerated approval narrative from 2024 and introduces years of delay.
UK MAA Submission Accelerating
In stark contrast to the FDA, the UK's MHRA held a constructive pre-submission meeting with uniQure. The company is now on track to submit a Marketing Authorization Application (MAA) for AMT-130 in Q3 2026 based on the 3-year data. This geographical pivot represents the fastest remaining path to commercialization.
Misaligned Commercial Spend
A severe contradiction exists in the financials: SG&A accelerated drastically, rising 84% YoY from $10.9M to $20.1M, explicitly due to 'employees recruited in 2025 to support commercial planning of AMT-130'. Because the US launch is now delayed indefinitely by the FDA, this elevated spend is highly premature and creates an unnecessary drag on the cash runway.
Pipeline Attrition: ALS Scrapped, Fabry Paused
The broader pipeline is thinning. The AMT-162 program for SOD1-ALS has been officially discontinued following an Independent Data Monitoring Committee review of safety (a serious adverse event/dose-limiting toxicity) and preliminary efficacy. Meanwhile, AMT-191 (Fabry) is showing promise (all 11 patients off ERT), but the mid- and high-dose cohorts remain paused due to Grade 3 liver enzyme elevations.
AMT-260 (Epilepsy) Execution Remains Stable
The AMT-260 program for refractory mesial temporal lobe epilepsy is progressing reliably. Enrollment for the first cohort (6 patients) is complete, and the second cohort expects to finish enrollment by mid-2026. A key clinical update on the first cohort is slated for the June 2026 Epilepsy Foundation conference.
Cash Runway Buys Patience
The silver lining to the clinical setbacks is the balance sheet. With $586.6M in cash and current investments, management projects runway into H2 2029. This extended timeline allows the company to absorb the FDA-mandated delays for AMT-130 without the immediate threat of dilutive equity raises.
Other KPIs
Decelerating. R&D spend fell 19% YoY from $36.1M in 25Q1. This reduction was driven by lower external program spend and a decrease in fair value of contingent consideration, somewhat offsetting the spike in SG&A.
Accelerating slightly off a low base, up from $1.6M in 25Q1, entirely due to an increase in license revenue. Contract manufacturing revenue has evaporated following the 2024 divestment of the Lexington facility.
uniQure reached an agreement with CSL Behring and Genezen to terminate uniQure's remaining supply and minimum purchase commitments for HEMGENIX after mid-2026. This fully removes uniQure from the manufacturing loop while preserving all future royalties and milestones.
Guidance
Stable. The company maintained its guidance that existing cash balances will fund operations for another 3+ years. However, this projection will face a stress test once the cost parameters of the newly required FDA AMT-130 trial are defined.
Accelerating pivot. Management explicitly guided to submitting a Marketing Authorization Application to the UK's MHRA in Q3 2026, marking a complete strategic shift toward ex-US commercialization to salvage early value from the asset.
Next major pipeline catalyst. The company guided to presenting data from the first cohort (6 patients) with up to six months of follow-up at the Epilepsy Foundation Pipeline Conference.
Key Questions
SG&A Rationalization
With SG&A nearly doubling YoY due to US commercial planning for AMT-130, and the FDA now requiring a new clinical trial, will you immediately initiate a reduction in force for the US commercial team to protect the cash runway?
New AMT-130 Trial Parameters
Heading into the Q2 Type B meeting with the FDA, what is your baseline expectation for the size, duration, and cost of the new clinical trial, and is that projected cost fully baked into the H2 2029 cash runway guidance?
UK Commercial Viability
While an MHRA MAA submission is a positive step, what is the actual commercial and reimbursement outlook for a gene therapy in the UK National Health Service, and can it meaningfully offset the delayed US revenues?
Fabry Disease Program Ceiling
With the mid- and high-dose cohorts of AMT-191 paused due to liver toxicity, do you believe the lowest dose provides sufficient, durable enzyme activity to be commercially competitive without requiring dangerous immunosuppression?